Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
16 December 2017 |
Main ID: |
NCT03133741 |
Date of registration:
|
25/04/2017 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist
GA-3 |
Scientific title:
|
Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist (GA-3) |
Date of first enrolment:
|
March 1, 2017 |
Target sample size:
|
18 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT03133741 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Triple (Participant, Investigator, Outcomes Assessor).
|
Phase:
|
N/A
|
|
Countries of recruitment
|
Denmark
| | | | | | | |
Contacts
|
Name:
|
Filip K Knop, MD, PhD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
UHGentofte, Center for Diabetes Research |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Normal kidney function, liver function and hemoglobin levels.
Exclusion Criteria:
- Medication, Diabetes type 1 or 2, first degree relatives with Diabetes type 2
Age minimum:
18 Years
Age maximum:
70 Years
Gender:
Male
|
Health Condition(s) or Problem(s) studied
|
Glucose Metabolism Disorders
|
Intervention(s)
|
Other: GIP-A + Exendin[9-39]
|
Other: GIP-A
|
Other: GLP-1 receptor antagonist Exendin[9-39]
|
Other: Placebo
|
Primary Outcome(s)
|
Insulin levels
[Time Frame: 240 minutes]
|
Secondary ID(s)
|
UHG-CFD-GIPANTA-3
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|